Rhythm Pharmaceuticals (RYTM)
NASDAQ:RYTM
Want to see RYTM full AI Analyst Report?
RYTM Stock Chart & Stats
$88.69
-$0.41(-0.68%)
At close: 4:00 PM EST
$88.69
-$0.41(-0.68%)
Day’s Range― - ―
52-Week Range$60.70 - $122.20
Previous CloseN/A
Volume91.33K
Average Volume (3M)707.88K
Market Cap
$5.79B
Enterprise Value$6.22B
Total Cash (Recent Filing)$340.63M
Total Debt (Recent Filing)$227.02M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Aug 04, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding68,593,575
10 Day Avg. Volume533,135
30 Day Avg. Volume707,878
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)50.02
Price to Sales (P/S)36.66
P/FCF Ratio-59.64
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue28.63
Enterprise Value/Gross Profit32.02
Enterprise Value/Ebitda-34.00
Forecast
1Y Price Target
$136.77Price Target Upside54.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.15
Revenue Forecast (FY)$298.08M
Bulls Say, Bears Say
Bulls Say
High Revenue Growth And Gross MarginsRevenue scaled materially from $23.6M (2022) to $217.2M TTM with very high gross margins (~88–91%). Durable unit economics from a chronic specialty therapy mean incremental sales can flow to the bottom line as SG&A and R&D growth moderate, supporting long-term profitability potential.
Regulatory Approval Expands Labeled Patient PopulationThe FDA expanded IMCIVREE's indication to acquired hypothalamic obesity, making it the first approved therapy in this niche. This structural approval enlarges the addressable population (US estimate ~10,000), strengthens product-market fit in rare obesity, and supports sustainable prescription flow and payer engagement.
Multi-quarter Cash Runway To Fund ExecutionApproximately $341M in cash and a stated runway of at least 24 months provide durable funding for commercialization (US, Japan, EU launches), payer access work, and near-term clinical milestones. This reduces near-term financing risk and allows execution of growth initiatives and trials over the next 2–6 months.
Bears Say
Sustained Negative Operating And Free Cash FlowOperating cash flow and free cash flow remain meaningfully negative (-$119.5M and -$120.5M TTM). Persistent cash burn has been stable over several years, forcing dependence on external capital and constraining the firm's ability to self-fund expansion or absorb setbacks without dilutive financing.
Elevated Leverage And Declining EquityTotal debt rose to $227M with debt-to-equity around 1.85x and equity shrinking materially from 2021 levels. This higher leverage reduces balance-sheet flexibility, increases refinancing and interest-rate exposure, and limits capacity to fund opportunistic investments or absorb operational shocks.
Rapid Operating Expense Growth Limiting Leverage GainsSG&A surged ~62.7% YoY to support HO launch (salesforce expansion, stock comp, marketing) while R&D also rose. Rapid expense escalation can outpace early revenue gains, delaying operating leverage and the transition to sustainable profitability unless revenue growth accelerates or cost growth is reined in.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
Rhythm Pharmaceuticals lowest stock price was $60.70 and its highest was $122.20 in the past 12 months.
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is $5.79B.
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
Rhythm Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 62 days.
How were Rhythm Pharmaceuticals’s earnings last quarter?
Rhythm Pharmaceuticals released its earnings results on May 05, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.822 by -$0.008.
Is Rhythm Pharmaceuticals overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals’s price is currently Undervalued.
Does Rhythm Pharmaceuticals pay dividends?
Rhythm Pharmaceuticals does not currently pay dividends.
What is Rhythm Pharmaceuticals’s EPS estimate?
Rhythm Pharmaceuticals’s EPS estimate is -0.81.
How many shares outstanding does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals has 68,593,575 shares outstanding.
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Rhythm Pharmaceuticals reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.822. Following the earnings report the stock price went up 7.864%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
Currently, no hedge funds are holding shares in RYTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$136.77 (54.21% Upside)
$136.77 (54.21% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $930.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.50%
12-Months-Change
Fundamentals
Return on Equity
-203.25%
Trailing 12-Months
Asset Growth
14.39%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
RYTM Company Deck
RYTM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and regulatory picture: sequential revenue growth (5%), strong international acceleration (27% QoQ outside U.S.), an encouraging early HO launch (150+ start forms, broad prescriber base), EU marketing authorization and a progressing Japan filing, supported by a solid cash runway (~$341M). Offsetting these positives are meaningful increases in operating expenses (notably SG&A up ~62.7% YoY), ongoing GAAP losses (Q1 EPS -$0.83) and near-term variability and uncertainty tied to payer policy timing, inventory effects and the pace of clinical-to-commercial conversions. Overall, the operational momentum and regulatory wins outweigh the financial and execution risks highlighted for the near term.View all RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
$136.77
▲(54.21% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Ownership Overview
0.82% Insiders
31.22% Mutual Funds
50.73% Other Institutional Investors
1.90% Public Companies and
Individual Investors